Limited Flash Sale: 35% Off All Research Compounds | Code: 35forall
Summit Labs Logo

Retatrutide (GLP-3 RT 30mg): Triple Receptor Research

Published 6 min read

Contents

Retatrutide (GLP-3 RT 30mg): A Research Overview of Triple Receptor Activity

For laboratory and research use only. Not for human consumption.

Retatrutide (developmental code LY3437943) is an investigational peptide designed to activate three receptors with one molecule: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. The FDA has not approved it. This overview covers what the published pharmacology says about its receptor activity and half-life, and what a laboratory should weigh when handling and verifying research-grade material. It is written for laboratory readers and does not address use in people or animals. Nothing here is a claim about the effects of any product.

What "GLP-3" means

Sellers and search engines often label retatrutide "GLP-3." That is shorthand, not an established pharmacological class. Published reviews describe the compound as a lipidated peptide of 39 amino acids built to act at three receptors at once, which is why the literature calls it a triple agonist. This page uses both names so researchers searching either term reach the same compound.

Receptor pharmacology

The GIP, GLP-1, and glucagon receptors are class B G protein-coupled receptors that signal mainly through Gs and cyclic AMP. In vitro work usually measures that signal in cell lines expressing the recombinant human receptor and reports potency as an EC50 relative to the native hormone.

The original characterization, published in Cell Metabolism in 2022 and summarized in the developer's medical information, reported an uneven profile. At the human GIP receptor, retatrutide was about 8.9-fold more potent than native GIP. At the human GLP-1 receptor it was about 2.5-fold less potent than native GLP-1, and at the human glucagon receptor about 2.9-fold less potent than native glucagon. The molecule is therefore weighted toward GIP receptor activity, with more balanced activity at the other two.

Two points matter for assay design. These ratios are relative to native ligands, so "less potent" at one receptor does not mean weak or absent signaling. And values from different publications depend on the cell system, receptor expression level, and readout, so selectivity work is cleaner when all three receptors are run in parallel under matched conditions.

Half-life and albumin binding

In a Phase 1 study in healthy participants, the developer reported a mean half-life of about 6 days. Reviews attribute this to a fatty diacid moiety on the peptide that binds albumin reversibly and slows clearance. That figure describes the investigational compound in published clinical reports. It is not a specification for any supplier's material, and it does not describe how research material behaves in a laboratory system.

The albumin-binding design does matter in vitro. Serum or albumin in assay media can change the apparent potency of a lipidated peptide, so results from serum-free buffer and from serum-containing media are not directly comparable. Researchers should record the albumin content of their media.

Laboratory handling and stability

Lyophilized peptides are generally more stable than peptides in solution. The usual degradation routes are hydrolysis, oxidation, and aggregation, and moisture, heat, light, and repeated freeze-thaw cycles speed all three. Lipidated peptides add one more problem: they can adsorb to some plastics and glass, which lowers the measured concentration of dilute solutions.

Solvent choice, container material, and storage conditions should follow the lot documentation and the institution's own validated procedures. Reconstitution and aliquoting methods belong in a laboratory SOP, so this page does not give them.

Verifying identity and purity

A Certificate of Analysis is only as useful as the methods behind it. For a peptide of this size, roughly 4.7 kDa, a COA should report HPLC purity with the method conditions and an intact-mass result from mass spectrometry that matches the expected molecular weight.

Lipidation changes what the numbers look like. The expected mass must include the fatty diacid modification, and a modified peptide usually elutes later on a reversed-phase column than an unmodified one of similar length because it is more hydrophobic. A COA that reports a mass without saying what it was compared against, or a chromatogram without the gradient and detection wavelength, leaves the reader unable to judge the result.

Two details are easy to miss. HPLC purity is the share of the UV-absorbing peak area, which is not the same as net peptide content, because net content accounts for water and counterions such as trifluoroacetate or acetate. And the lot number printed on the COA should match the lot on the vial in hand. The Certificate of Analysis for the current lot is available on the product page.

Designing a clean in vitro comparison

A few controls make receptor data easier to interpret. Run the native hormones (GIP, GLP-1, and glucagon) as reference agonists on the same plate, so potency can be expressed as a ratio within one experiment. Include a parental cell line that lacks the receptor to confirm the signal depends on it. In cAMP assays a phosphodiesterase inhibitor is commonly added to stabilize the signal, and its presence should be reported. Fit full concentration-response curves rather than single points, and report the curve fit and its confidence interval along with the EC50.

Peptide concentration is the other common source of error. Weighing lyophilized powder and treating it as 100% peptide overstates the concentration, because the powder also contains water and counterions. Correcting the stock concentration with the net peptide content from the lot documentation removes much of that error.

Regulatory status and research use only

Retatrutide is an investigational compound under clinical development, and the FDA has not approved it. Summit Labs supplies this material for laboratory research use only. It is not a drug, food, or cosmetic, it has not been evaluated by the FDA, and it is not for human or veterinary use. Nothing on this page is medical advice or a description of how any person should use this material.

Product specifications and COA

For product specifications and the lot Certificate of Analysis, see the Retatrutide 30mg (GLP-3 RT) product page.

Sources

Back to Shop

For laboratory research use only. Not for human or veterinary use.